Cancer therapy induced cardiotoxicity: monitoring

1. Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A, Schwartz PE, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987; 82:1109-18.10.1016/0002-9343(87)90212-9Open DOISearch in Google Scholar

2. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and non invasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978; 62:857-64.Search in Google Scholar

3. Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol. 1984; 2:112-7.10.1200/JCO.1984.2.2.112Search in Google Scholar

4. Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Dxorubicin cardiotoxicity serial endomyocardial biopsies and systolic time intervals. JAMA. 1978; 240: 1603-6.10.1001/jama.1978.03290150049023Open DOISearch in Google Scholar

5. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of ACC/AHA/ESC scientific statement; endomyocardial biopsy in the management of cardiovascular disease. J Am Coll Cardiol. 2007; 50:1941.10.1016/j.jacc.2007.09.008Open DOISearch in Google Scholar

6. Zaret BL. Imaging in patients receiving cardiotoxic chemotherapy. In Zaret BL, Beller GA. Clinical nuclear cardiology. Philadelphia. Elsevier Mosby; 2005.Search in Google Scholar

7. Strauss WH, Zaret BL, Hurley PJ, Natarajan TK, Pitt B. A scintigraphic method for measuring left ventricular ejection fraction in man without cardiac catheterization. Am J Cardiol. 1971; 28:575.10.1016/0002-9149(71)90100-7Open DOISearch in Google Scholar

8. Starling MR, Dell’Italia LJ, Walsh RA, Little WC, Benedetto AR, Nusynowitz ML. Accurate estimates of absolute ventricular volumes from equilibrium radionuclide angiographic count data using a simple geometric attenuation correction. J Am Coll Cardiol. 1984; 3:789.10.1016/S0735-1097(84)80256-9Open DOISearch in Google Scholar

9. van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, et al. Comparison and reproducibility of visual echocardiographic and quantitative radio-nuclide left ventricular ejection fractions. Am J Cardiol. 1996; 77:843-50.10.1016/S0002-9149(97)89179-5Open DOISearch in Google Scholar

10. Zaret BL. Imaging in patients receiving cardiotoxic chemotherapy. In Zaret BL, Beller GA. Clinical nuclear cardiology. Philadelphia. Elsevier Mosby; 2005.Search in Google Scholar

11. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97: 2869-79.10.1002/cncr.11407Open DOISearch in Google Scholar

12. Ford P , Chatziioannou S, Moore H, Dhekne RD. Overestimation of the LVEF by quantitative gated SPECT in simulated left ventricles. J Nucl Me. 2001; 42: 454-9.Search in Google Scholar

13. Ioannidis JP, Trikalinos TA, Danias PG. Electrocardiogram gated single-photon emission computed tomography versus cardiac magnetic resonance imaging for the assessment of left ventricular volumes and ejection fraction: a meta-analysis. J Am Coll Cardiol. 2002; 39:2059-68.10.1016/S0735-1097(02)01882-XOpen DOISearch in Google Scholar

14. Kondo C, Fukushima K, Kusakabe K. Measurement of left ventricular volumes and ejection fraction by quantitative gated SPECT. Contrast ventriculography and magnetic resonance imaging: a meta-analysis. Eur J Nucl Med Mol Imaging. 2003; 30:851-8.10.1007/s00259-003-1146-912677303Open DOISearch in Google Scholar

15. Daou D, Harel F, Helal BO, Fourme T, Colin P, Lebtahi R, et al. Electrocardiographically gated blood pool SPECT and left ventricular function: comparative value of 3 methods for ejection fraction and volume estimation. J Nucl Med. 2001; 42:1043-9.Search in Google Scholar

16. Wright GA, Thackray S, Howey S, Cleland JG. Left ventricular ejection fraction and volumes from gated blood pool SPECT: comparison with planar gated blood pool imaging and assessment of repeatability in patients with heart failure. J Nucl Med. 2003; 44: 494-8.Search in Google Scholar

17. Van Kriekingag SD, Berman DS, Germano G. Automatic quantification of left ventricular ejection fraction from gated blood pool tomography. J Nucl Cardiol. 1999; 6:498-506.10.1016/S1071-3581(99)90022-3Open DOISearch in Google Scholar

18. He ZX, Cwajg E, Preslar JS, Mahmarian JJ, Verani MS. Accuracy of left ventricular ejection fraction determined by gated myocardial perfusion SPECT with Tl-201 and Tc-99m sestamibi: comparison with first-pass radionuclide angiography. J Nucl Cardiol. 1999; 6:412-7.10.1016/S1071-3581(99)90007-7Search in Google Scholar

19. Hida S, Chikamori T, Tanaka H, Usui Y, Igarashi Y, Nagao T, et al. Diagnostic value of left ventricular function after stress and at rest in the detection of multivessel coronary artery disease as assessed by electrocardiogram-gated SPECT. J Nucl Cardiol. 2007; 14:68-74.10.1016/j.nuclcard.2006.10.019Open DOISearch in Google Scholar

20. De Winter O, Velghe A, Van de Veire N, De Bondt P, De Buyzere M, Van De Wiele C, et al. Incremental prognostic value of combined perfusion and function assessment during myocardial gated SPECT in patients aged 75 years or older. J Nucl Cardiol. 2005; 12:662-70.10.1016/j.nuclcard.2005.08.002Open DOISearch in Google Scholar

21. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group. J Am Soc Echocardiogr. 2005; 18: 1440-63.10.1016/j.echo.2005.10.005Open DOISearch in Google Scholar

22. Pombo JF, Troy BL, Russell RO Jr. Left ventricular volumes and ejection fraction by echocardiography. Circulation. 1971; 43:480-90.10.1161/01.CIR.43.4.480Open DOISearch in Google Scholar

23. Lee D, Fuisz AR, Fan PH, Hsu TL, Liu CP, Chiang HT. Real-time 3-dimensional echocardiographic evaluation of left ventricular volume: correlation with magnetic resonance imaging. J Am Soc Echocardiogr. 2001; 14: 1001-9.10.1067/mje.2001.113647Open DOISearch in Google Scholar

24. Cottin Y, Touzery C, Coudert B, Gilles A, Walker P, Massing JL, et al. Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J. 1995; 73:61-4.10.1136/hrt.73.1.61Open DOISearch in Google Scholar

25. Movahe MR. Interference of breast implants with echocardiographic image acquisition and interpretation. Cardiovac Ultrasound. 2007; 5:9.10.1186/1476-7120-5-9Search in Google Scholar

26. Rajappan K, Bellenger NG, Anderson L, Pennell DJ. The role of cardiovascular magnetic resonance in heart failure. Eur Heart Fail. 2000; 2:241-52.10.1016/S1388-9842(00)00096-9Open DOISearch in Google Scholar

27. Wassmuth R, Lentzsch S, Erdbruegger U, Schulz- Menger J, Doerken B, Dietz R, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - A pilot study. Am Heart J. 2001; 141:1007-13.10.1067/mhj.2001.11543611376317Open DOISearch in Google Scholar

28. McKenna DA, Laxpati M, Colletti PM. The prevalence of incidental findings at cardiac MRI. Open Cardiovasc Med J. 2008; 2:30-5.10.2174/1874192400802010020257057318949093Open DOISearch in Google Scholar

29. Juergens KU, Grude M, Maintz D, Fallenberg EM, Wichter T, Heindel W, et al. Multi-detector row CT of left ventricular function with dedicated analysis software versus MRI: Initial experience. Radiology. 2004; 230:403-10.10.1148/radiol.230203004214668428Open DOISearch in Google Scholar

30. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997; 96:2641-8.10.1161/01.CIR.96.8.2641Open DOISearch in Google Scholar

31. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol. 1999; 17:2237-43.10.1200/JCO.1999.17.7.223710561281Search in Google Scholar

32. Suzubi T, Hayashi D, Yamarak T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998; 136:362-3.10.1053/hj.1998.v136.899089704703Open DOISearch in Google Scholar

33. Nousianinen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptide as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma. Eur J Haematol. 1999; 62:135-41.10.1111/j.1600-0609.1999.tb01734.x10052718Open DOISearch in Google Scholar

34. U.S. Preventive Services Task Force. Screening adults for lipid disorders: recommendations and rationale. Am J Prev Med. 2001; 20:73-6.11306235Search in Google Scholar

35. Ridker PM, on behalf of the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003; 108: 2292-7. 10.1161/01.CIR.0000100688.17280.E614609996Search in Google Scholar